Abstract
Aim: To update overall survival (OS) results from a previous network meta analysis comparing the relative clinical efficacy of epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR TKIs) for EGFR mutation positive (EGFR+) advanced non-small-cell lung cancer (NSCLC). Materials & methods: A Bayesian network meta analysis was conducted using updated/mature randomized controlled trial OS results in response to first-line EGFR TKI therapies. Results: Dacomitinib showed a numerical improvement of OS relative to other EGFR TKIs: afatinib (hazard ratio [HR]: 0.87; 95% credible interval [CrI]: 0.61-1.24), erlotinib (HR: 0.79; 95% CrI: 0.44-1.42), gefitinib (HR: 0.75; 95% CrI: 0.59-0.95) and osimertinib (HR: 0.94; 95% CrI: 0.68-1.29). Conclusion: Dacomitinib should be considered as a first-line treatment option for patients diagnosed with advanced EGFR+ NSCLC.
Keywords:
EGFR; EGFR mutation positive; TKI; network meta analysis; non-small-cell lung cancer; overall survival; tyrosine kinase inhibitors.
MeSH terms
-
Acrylamides / pharmacology
-
Acrylamides / therapeutic use
-
Afatinib / pharmacology
-
Afatinib / therapeutic use
-
Aniline Compounds / pharmacology
-
Aniline Compounds / therapeutic use
-
Bayes Theorem
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Disease-Free Survival
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Erlotinib Hydrochloride / pharmacology
-
Erlotinib Hydrochloride / therapeutic use
-
Gain of Function Mutation
-
Gefitinib / pharmacology
-
Gefitinib / therapeutic use
-
Humans
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Neoplasm Staging
-
Network Meta-Analysis
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolinones / pharmacology
-
Quinazolinones / therapeutic use*
-
Randomized Controlled Trials as Topic
Substances
-
Acrylamides
-
Aniline Compounds
-
Protein Kinase Inhibitors
-
Quinazolinones
-
osimertinib
-
Afatinib
-
dacomitinib
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors
-
Gefitinib